Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.32 |
| ▸ | DRD1 | P21728 | 5/20 | 0.32 |
| ▸ | DRD4 | P21917 | 5/20 | 0.32 |
| ▸ | DRD5 | P21918 | 5/20 | 0.32 |
| ▸ | DRD3 | P35462 | 5/20 | 0.32 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.30 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10181219 | 0.86 | RORC (0.38) | — | |
| SCHEMBL10179691 | 0.83 | DRD2 (0.35) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL7881790 | 0.81 | DRD2 (0.36) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL504734 | 0.80 | PDK1 (0.47) | PDK2 | |
| SCHEMBL21193763 | 0.77 | CXCR2 (0.32) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL22550636 | 0.77 | — | — | |
| SCHEMBL17633413 | 0.75 | DRD2 (0.32) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL19253110 | 0.75 | CXCR2 (0.31) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL15635869 | 0.74 | DRD2 (0.36) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL29206746 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4305040-A1 | TRICYCLIC PYRIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022189387-A1 | TRICYCLIC PYRIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-15 | — | — | WO | disclosed |
| US-20220152023-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-19 | — | — | US | disclosed |
| EP-3959206-A1 | INHIBITORS OF TRPC6 | Boehringer Ingelheim International GmbH (DE) | 2022-03-02 | — | — | EP | disclosed |
| WO-2020208002-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-10-15 | — | — | WO | disclosed |
| US-10385036-B2 | Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180273504-A1 | Sulfonamide-Substituted Indole Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2018-09-27 | — | — | US | disclosed |
| CN-103965168-A | Aryl/heteroaryl-substituted 2-aminopyridine inhibitor for protein kinase | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD | 2014-08-06 | — | — | CN | disclosed |
| CN-103965161-A | Substituted 2-aminopyridine inhibitor for protein kinase | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD | 2014-08-06 | — | — | CN | disclosed |
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| EP-2414340-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | DRD2 979/4885DRD1 1757/4885DRD4 2393/4885 |
| US-20180273504-A1 | Sulfonamide-Substituted Indole Modulators of RORC2 and Methods of Use Thereof | RORC, RORB, RORA | DRD2 2021/4885DRD1 2479/4885DRD4 2412/4885 |
| US-20220152023-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC3 | DRD2 2081/4885DRD1 2497/4885DRD4 2792/4885 |
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | DRD2 267/4885DRD1 473/4885DRD4 674/4885 |
| US-10385036-B2 | Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof | RORC, RORB, RORA | DRD2 2524/4885DRD1 2794/4885DRD4 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.